SLNO

Company Overview — What Does SOLENO THERAPEUTICS INC Do?

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. SOLENO THERAPEUTICS INC (SLNO) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Anish Bhatnagar and employs approximately 30 people, headquartered in Palo Alto, California. With a market capitalization of $1.9B, SLNO is one of the notable companies in the Healthcare sector.

SOLENO THERAPEUTICS INC (SLNO) Stock Rating — Reduce (April 2026)

As of April 2026, SOLENO THERAPEUTICS INC receives a Reduce rating with a composite score of 32.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SLNO ranks #2,346 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, SOLENO THERAPEUTICS INC ranks #282 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SLNO Stock Price and 52-Week Range

SOLENO THERAPEUTICS INC (SLNO) currently trades at $52.63. The stock gained $0.12 (0.2%) in the most recent trading session. The 52-week high for SLNO is $90.32, which means the stock is currently trading -41.7% from its annual peak. The 52-week low is $32.15, putting the stock 63.7% above its annual trough. Recent trading volume was 3.6M shares, reflecting moderate market activity.

Is SLNO Overvalued or Undervalued? — Valuation Analysis

SOLENO THERAPEUTICS INC (SLNO) carries a value factor score of 41/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 131.28x, compared to the Healthcare sector average of 23.63x — a premium of 456%. The price-to-book ratio stands at 6.02x, versus the sector average of 2.75x. The price-to-sales ratio is 27.44x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, SLNO trades at 59.21x EV/EBITDA, versus 6.34x for the sector.

Overall, SLNO's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

SOLENO THERAPEUTICS INC Profitability — ROE, Margins, and Quality Score

SOLENO THERAPEUTICS INC (SLNO) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -22.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -17.6% versus the sector average of -33.1%.

On a margin basis, SOLENO THERAPEUTICS INC reports gross margins of 98.1%, compared to 71.5% for the sector. The operating margin is 6.8% (sector: -66.1%). Net profit margin stands at 12.5%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SLNO Debt, Balance Sheet, and Financial Health

SOLENO THERAPEUTICS INC has a debt-to-equity ratio of 25.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.80x, indicating strong short-term liquidity. Total debt on the balance sheet is $50M. Cash and equivalents stand at $247M.

SLNO has a beta of 0.79, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for SOLENO THERAPEUTICS INC is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

SOLENO THERAPEUTICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, SOLENO THERAPEUTICS INC reported revenue of $99M and earnings per share (EPS) of $0.40. Net income for the quarter was $-99M. Gross margin was 98.1%. Operating income came in at $-110M.

In FY 2025, SOLENO THERAPEUTICS INC reported revenue of $190M and earnings per share (EPS) of $0.40. Net income for the quarter was $21M. Gross margin was 98.6%. Operating income came in at $9M.

In Q3 2025, SOLENO THERAPEUTICS INC reported revenue of $66M and earnings per share (EPS) of $0.49. Net income for the quarter was $26M. Gross margin was 98.3%. Operating income came in at $22M.

In Q2 2025, SOLENO THERAPEUTICS INC reported revenue of $33M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-5M. Gross margin was 97.9%. Operating income came in at $-7M.

Over the past 8 quarters, SOLENO THERAPEUTICS INC has demonstrated a growth trajectory, with revenue expanding from $0 to $99M. Investors analyzing SLNO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SLNO Dividend Yield and Income Analysis

SOLENO THERAPEUTICS INC (SLNO) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SLNO Momentum and Technical Analysis Profile

SOLENO THERAPEUTICS INC (SLNO) has a momentum factor score of 19/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

SLNO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, SOLENO THERAPEUTICS INC (SLNO) ranks #282 out of 838 stocks based on the Blank Capital composite score. This places SLNO in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SLNO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SLNO vs S&P 500 (SPY) comparison to assess how SOLENO THERAPEUTICS INC stacks up against the broader market across all factor dimensions.

SLNO Next Earnings Date

No upcoming earnings date has been announced for SOLENO THERAPEUTICS INC (SLNO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SLNO? — Investment Thesis Summary

The quantitative profile for SOLENO THERAPEUTICS INC suggests caution. The quality score of 29/100 flags below-average profitability. Momentum is weak at 19/100, a headwind for near-term performance. High volatility (stability score 38/100) increases portfolio risk.

In summary, SOLENO THERAPEUTICS INC (SLNO) earns a Reduce rating with a composite score of 32.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SLNO stock.

Related Resources for SLNO Investors

Explore more research and tools: SLNO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SLNO head-to-head with peers: SLNO vs AZN, SLNO vs SLGL, SLNO vs VMD.